Evidence map›Paper›PMID 26257819›Full record

ArticleNano today2012

Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

Mar Creixell, Nicholas A Peppas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 319 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Small interfering RNA: From designing to therapeutic in cancer.Journal, genetic engineering & biotechnology · 2025
    Review
  10. Review
  11. Article
  12. Nanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mar CreixellDepartment of Chemical Engineering, C0400, The University of Texas at Austin, Austin, TX 78712, USA.
Nicholas A PeppasDepartment of Chemical Engineering, C0400, The University of Texas at Austin, Austin, TX 78712, USA ; Department of Biomedical Engineering, C0800, The University of Texas at Austin, Austin, TX 78712, USA ; College of Pharmacy, C0400, The University of Texas at Austin, Austin, TX 78712, USA.
The University of Texas at Austin · US

Funding

TRANS-NETWORK PROJECTSU54CA143837 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2009 to 2014
$10.8M
NCI NIH HHS U54 CA143837
6 · The paper itself

Abstract

There are two main mechanisms by which cells become multidrug resistant (MDR): by increasing drug efflux pumps on the cell membrane and by increasing anti-apoptotic pathways. The use of nanotechnology to develop nanodelivery systems has allowed researchers to overcome limitations of antineoplastic drugs by increasing the solubility of the drug and decreasing the toxicity to healthy tissues. By encapsulating drugs into nanoparticles that bypass the efflux pumps, drug efflux is reduced, hence increasing the intracellular concentration of the drug. siRNA has the ability to disrupt cellular pathways by knocking down genes, opening the door to down regulating anti-apoptotic pathways. The use of nanocarriers to deliver siRNA, prevents both renal clearance and RNase degradation by protecting siRNA chains, increasing their half life in blood. It has been suggested that co-delivering drugs and siRNA together in the same delivery system would be more effective in overcoming resistance of cancer cells than co-treatment of cancer cells with delivery systems carrying either siRNA or drugs. In this study we discuss the progress of nanoscale co-delivery systems in overcoming multidrug cancer resistance.

Indexed as

Cancer therapyCo-deliveryDoxorubicinMulti drug resistance (MDR)NanoparticlessiRNA

Identifiers

PMID26257819
PMCPMC4527553
OpenAlexW1988816960

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.